August 5th 2025
FDA approves Biktarvy for HIV treatment in patients not virologically suppressed, enhancing options for those restarting antiretroviral therapy.
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Exploring HIV Long-Acting Injectable Uptake: How Pharmacists Can Encourage Long-Acting Injectables to Stem the...
1.5 Credits / HIV/AIDS, Infectious Disease
View More
Optimizing the Uptake of Long-Acting Injectables in HIV Treatment and Prevention: Considerations for Managed C...
1.5 Credits / HIV/AIDS, Infectious Disease
View More
PBM Challenges and the Evolving Role of Oncology Pharmacists in Community Practices
0.75 Credit / Oncology, Law
View More
Discipline Decoded: Navigating Pharmacy Law and Disciplinary Cases (Pharmacy Technician Credit)
1.0 Credit / General Pharmacy, Law
View More
Discipline Decoded: Navigating Pharmacy Law and Disciplinary Cases
1.0 Credit / General Pharmacy, Law
View More
Securing the Supply Chain: The Pharmacists’ Role in DSCSA Compliance
1.0 Credit / Law
View More
Biktarvy Indication Expanded by FDA for Resistant HIV
February 27th 2024The new approval is supported by the phase 3 Study 4030, which evaluated the efficacy, safety, and tolerability profile of Biktarvy in a broad range of people with HIV-1 with or without pre-existing NRTI resistance, including those with the M184V/I resistance.